NovoCure Limited Stock Price, News, Quote & History

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.

NovoCure Limited

Novocure Reports Third Quarter 2025 Financial Results

Novocure to Present New Research for Tumor Treating Fields Therapy at European Association of Neuro-Oncology Meeting and the European Society for Medical Oncology Congress

Novocure to Report Third Quarter 2025 Financial Results

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer

Novocure Announces Upcoming Investor Events

Novocure Announces Coverage of Tumor Treating Fields Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

5 US Longevity and Anti-aging Stocks to Watch in 2025

Latest News

Trigg Secures High-Grade Tungsten Mines & Two Drill Programs

Quarterly Activities Report for the Quarter ended 30 September 2025

Quarterly Activities/Appendix 5B Cash Flow Report

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

FireFly appoints highly experienced resources specialist as Non-Executive Director

Latest News

Outlook Reports

Featured Stocks

Browse Companies